Treating low HDL--from bench to bedside

Area of Science:

• Cardiovascular Science
• Metabolic Research
• Pharmacology

Background:

• The inverse relationship between plasma high-density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD) risk is established.
• Developing effective HDL-targeting therapeutics is challenging due to HDL's heterogeneity and complex metabolism.
• HDL plays a crucial role in reverse cholesterol transport and preventing atherogenesis.

Purpose of the Study:

• To review recent advances in understanding HDL metabolism and its role in atherogenesis.
• To discuss current lipid-modifying drugs and novel therapeutic strategies targeting HDL.
• To provide an overview of the therapeutic landscape for modulating HDL-C levels.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of existing data on lipid-modifying drugs and HDL-targeted therapies.
• Synthesis of information on HDL metabolism and its implications in cardiovascular disease.

Main Results:

• Current lipid-modifying drugs demonstrate varying effects on HDL-C levels.
• Novel therapeutic strategies are under development to specifically target HDL function and metabolism.
• Understanding HDL heterogeneity is key to developing effective treatments.

Conclusions:

• Effective HDL-targeted therapies remain a significant goal in cardiovascular disease prevention.
• Further research into HDL metabolism and composition is essential for therapeutic advancements.
• A combination of existing and novel strategies may be necessary to optimize HDL-C levels and reduce CHD risk.